ARMSTRONG ET AL.: '8000 Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: preliminary data from a phase-2 study' EUR. J. CANCER SUPPLEMENTS vol. 7, no. 2, September 2009, page 450, XP026690328 (B1)

YUAN Y ET AL: "Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions", HUMAN PATHOLOGY, SAUNDERS, PHILADELPHIA, PA, US, vol. 40, no. 10, 1 October 2009 (2009-10-01), pages 1453-1460, XP026599723, ISSN: 0046-8177, DOI: 10.1016/J.HUMPATH.2009.02.013 [retrieved on 2009-05-19] (B1)

CN-A- 101 139 613 (B1)

CN-A- 101 440 130 (B1)

CONDE F P ET AL: "The Aspergillus toxin restriction is a suitable cytotoxic agent for generation of immunoconjugates with monoclonal antibodies directed against human carcinoma cells", EUROPEAN JOURNAL OF BIOCHEMISTRY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 178, no. 3, 2 January 1989 (1989-01-02), pages 795-802, XP002368963, ISSN: 0014-2956, DOI: 10.1111/J.1432-1033.1989.TB14511.X (B1)

DATABASE UNIPROT [Online] 05 February 2008 NISHIYAMA ET AL., XP008164405 Database accession no. A9SZW6_PHYPA. (B1)

DATABASE UNIPROT [Online] 28 July 2009 LIM ET AL., XP008164408 Database accession no. C5A929_BURGL (B1)

DATABASE UNIPROT [Online] 29 April 2008 COPELAND ET AL., XP008164407 Database accession no. B1G510_9BURK (B1)

MANTOVANI L T ET AL: "Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19", EUROPEAN JOURNAL OF CANCER, PERGAMON, vol. 30, no. 3, 1 January 1994 (1994-01-01), pages 363-369, XP026207901, ISSN: 0959-8049, DOI: 10.1016/0959-8049(94)90257-7 [retrieved on 1994-01-01] (B1)

Patrizia Casalini ET AL: "Use of combination of monoclonal antibodies directed against three distinct epitopes of a tumor-associated antigen: Analysis of cell binding and internalization", International Journal of Cancer, vol. 48, no. 2, 10 May 1991 (1991-05-10), pages 284-290, XP055218102, ISSN: 0020-7136, DOI: 10.1002/ijc.2910480222 (B1)

SINGH RAJEEVA ET AL: "Antibody-cytotoxic agent conjugates: preparation and characterization", METHODS IN MOLECULAR BIOLOGY, HUMANA PRESS INC, NJ, US, vol. 525, 1 January 2009 (2009-01-01), pages 445-467, XP008155909, ISSN: 1064-3745 (B1)

SMITH-JONES ET AL: "Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER, NY, US, vol. 35, no. 3, 17 March 2008 (2008-03-17) , pages 343-351, XP022537635, ISSN: 0969-8051, DOI: 10.1016/J.NUCMEDBIO.2007.12.008 (B1)

US-A1- 2003 028 009 (B1)

US-A1- 2003 148 406 (B1)

US-A1- 2003 157 090 (B1)

US-A1- 2003 229 208 (B1)

US-A1- 2003 233 675 (B1)

US-A1- 2004 031 072 (B1)

US-A1- 2004 087 478 (B1)

US-A1- 2004 157 214 (B1)

US-A1- 2004 170 630 (B1)

US-A1- 2004 180 386 (B1)

US-A1- 2005 025 763 (B1)

US-A1- 2005 244 901 (B1)

US-A1- 2006 030 524 (B1)

US-A1- 2006 110 771 (B1)

US-A1- 2006 228 349 (B1)

US-A1- 2006 239 910 (B1)

US-A1- 2007 041 985 (B1)

US-A1- 2007 098 719 (B1)

US-A1- 2007 294 782 (B1)

US-A1- 2008 081 047 (B1)

US-A1- 2008 104 734 (B1)

US-A1- 2008 181 888 (B1)

US-A1- 2008 227 704 (B1)

US-A1- 2008 260 748 (B1)

US-A1- 2009 104 215 (B1)

US-A1- 2009 136 516 (B1)

US-A1- 2009 169 547 (B1)

US-A1- 2009 186 027 (B1)

US-A1- 2009 215 165 (B1)

US-A1- 2009 280 128 (B1)

US-A1- 2009 285 813 (B1)

US-A1- 2009 317 921 (B1)

US-A1- 2009 324 491 (B1)

WO-A1-2008/031577 (B1)

WO-A1-2008/072723 (B1)

WO-A1-2009/087978 (B1)

WO-A1-97/11971 (B1)

WO-A2-2005/080431 (B1)

WO-A2-2006/116592 (B1)

WO-A2-2007/094754 (B1)

WO-A2-2008/101231 (B1)

WO-A2-94/29351 (B1)

CHEN J ET AL: "ANTIBODY-CYTOTOXIC AGENT CONJUGATES FOR CANCER THERAPY", EXPERT OPINION ON DRUG DELIVERY, INFORMA HEALTHCARE, GB, vol. 2, no. 5, 1 January 2005 (2005-01-01) , pages 873-890, XP008060439, ISSN: 1742-5247, DOI: 10.1517/17425247.2.5.873 (B1)